Free Trial

Oruka Therapeutics Q2 2023 Earnings Report

Oruka Therapeutics logo
$7.83 -1.09 (-12.22%)
As of 04/4/2025 04:00 PM Eastern

Oruka Therapeutics EPS Results

Actual EPS
-$14.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Oruka Therapeutics Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
Oruka Therapeutics announces preclinical data for ORKA-002
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

View Oruka Therapeutics Profile

More Earnings Resources from MarketBeat